STOCKHOLM, April 12, 2021 /PRNewswire/ -- SciBase Holding
AB ("SciBase") [STO:SCIB], a leading developer of augmented
intelligence-based solutions for skin disorders, announced today
the publication of a new clinical study supporting SciBase's
strategy to develop multiple clinical applications for the
Nevisense and Nevisense Go platforms.
The study is from the Swiss institute of Allergy and Asthma
Research (SIAF) and has been published in the European Journal of
Allergy and Clinical Immunology (Allergy). In the study Nevisense
was used to assess the skin barrier of patients with atopic
dermatitis (AD) and could accurately detect signs of atopic
dermatitis even on unaffected skin. The Nevisense measurement also
correlated with relevant biomarkers for atopic dermatitis.
SIAF, based in Davos, is a
world leader within applied allergy and asthma research. SIAF is
headed by Director Cezmi Akdis, who is also Professor of the
University of Zurich Medical Faculty and one of the directors of
the Christine Kühne Center for Allergy Research and Education.
Professor Akdis said, "Personalized and precision
medicine is becoming one of the most exciting areas in all of
medicine. Our research group has proposed the "epithelial
barrier hypothesis", which asserts that defective epithelial skin
barriers are the main reason for the initiation and increase of
allergic and autoimmune conditions such as asthma, atopic
dermatitis and inflammatory bowel disease. Furthermore, leakiness
of the gut epithelium is also implicated in conditions such as
diabetes, obesity, multiple sclerosis, rheumatoid arthritis and
others. Moreover, distant microinflammatory responses due to a
'leaky gut' and microbiome changes are suspected in Alzheimer's
disease, Parkinson's disease, chronic depression and autism
spectrum disorders.
Defective skin barrier is an important part of the
"epithelial barrier hypothesis". Atopic dermatitis alone affects
more than 10% of infants, and represents a huge health and
socioeconomic burden. Skin barrier assessment shows potential to be
clinically useful for early prediction of disease development,
improved diagnosis, disease follow-up and therapy evaluation.
This study shows that the Nevisense method can directly
assess the status of epithelial barrier using electrical impedance
spectroscopy (EIS). EIS was able to assess epithelial skin barrier
integrity, differentiate between patients and controls without AD
and characterize lesional and non-lesional skin of patients. EIS
also showed a significant correlation with biomarkers associated
with inflammatory pathways that may affect the skin barrier.
Furthermore, copy numbers of filaggrin, an essential skin barrier
molecule significantly correlated with EIS on non-lesional skin of
patients. These findings that are presented in the article strongly
indicates that Nevisense and the EIS method is a useful tool to
detect skin barrier dysfunction.'
SciBase CEO Simon Grant
commented, "This is an exciting new application area for
SciBase, and one where we have unique advantages. Barrier-related
diseases are widespread, and assessment of the barrier can help
better understand and treat patients. The study illustrates the
potential for Nevisense to become a valuable tool for clinicians
within AD and other epithelial barrier-related diseases. We see a
number of applications with broad market potential, and we are
working with SIAF and others to develop clinical products. For
SciBase this an important milestone in our strategy to develop
multiple clinical applications using our unique technology
platform."
The study can be found here :
https://onlinelibrary.wiley.com/doi/10.1111/all.14842?af=R.
For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com
Certified Advisor:
Avanza
Tel: +46 8 409 421 20
Email: ca@avanza.se
About SciBase and Nevisense
SciBase AB is a global medical technology company based in
Stockholm, Sweden that develops
unique point-of-care devices for the evaluation of skin disorders
such as skin cancer and atopic dermatitis. SciBase's first product,
Nevisense, helps clinicians detect melanoma, the most dangerous
type of skin cancer. Further development has led to Nevisense also
being used as a tool to assess the skin barrier and non-melanoma
skin cancer. Nevisense is based on substantial research and has
achieved excellent results in the largest clinical study ever
conducted on the detection of malignant melanoma. Nevisense is CE
marked in Europe, has TGA approval
in Australia and an FDA approval
(PMA) in the United States.
SciBase technology is based Electrical Impedance Spectroscopy (EIS)
combined with Artificial Intelligence (AI) algorithms that
interpret the varying electrical properties of human tissue to
detect malignancies and abnormalities. SciBase Holding AB is listed
on First North Growth Market ("SCIB"). Further information is
available at www.scibase.com.
About SIAF-SFI
The Swiss Institute of Allergy and Asthma Research (SIAF) is
a department of the foundation Swiss Research Institutes for High
Altitude Climate and Medicine Davos (SFI), an affiliated institute
of the University of Zurich, and
member of the Life Science Zurich Graduate School. SIAF members
play leading roles in national and international organizations,
such as European Academy of Allergy and Clinical Immunology and in
editorial boards and editorships of top Journals in the field of
allergy asthma and clinical immunology. At the same time, SIAF
fulfills teaching obligations in the University of Zurich. The research activities at SIAF are
focused on patient-relevant translational research and the
investigation of the immunological principles in the field of skin
atopic dermatitis, allergies and asthma to develop approaches for
new preventive and curative treatments for patients. SIAF also
promotes personalized medicine to develop treatment approaches that
are better tailored to the needs of individual patients. These
personalized medicine research activities are expected to not only
help to find tailor-made therapies but also to develop more precise
diagnosis. The continuously growing SIAF is one of the most cited
and leading institutes in its area worldwide with more than 50,000
citations and 1,000 original research articles in the last 20
years. SIAF organizes the internationally renowned World Immune
Regulation Meeting (WIRM) in Davos
every year. SIAF works in close collaboration with the Christine
Kühne-Center for Allergy Research and Education (CK-CARE),
Davos. Further information is
available at www.siaf.uzh.ch.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/scibase/r/new-clinical-study-shows-nevisense-potential-for-assessment-of-skin-barrier-and-atopic-dermatitis,c3323147
The following files are available for download:
https://mb.cision.com/Main/12371/3323147/1399791.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/new-clinical-study-shows-nevisense-potential-for-assessment-of-skin-barrier-and-atopic-dermatitis-301266438.html
SOURCE SciBase